Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCIOS/MARION MERRELL DOW $10.5 MIL. ALZHEIMER’s RESEARCH ALLIANCE

Executive Summary

SCIOS/MARION MERRELL DOW $10.5 MIL. ALZHEIMER's RESEARCH ALLIANCE will give Marion Merrell Dow exclusive worldwide rights to develop and market any Alzheimer's drugs discovered during the collaboration between the two firms. Announced July 6, the deal will give Scios milestone payments and royalties in addition to $10.5 mil. in research funding over a five-year period, the Mountain View, Calif.-based company said. The agreement does not include a Marion Merrell Dow equity investment in publicly-traded Scios (formerly Cal Bio). Both Scios and MMD will form research teams to focus on developing drugs that prevent the formation of beta-amyloid plaques in the brain. Central to the research effort is a transgenic mouse developed by Scios that exhibits amyloid plaques resembling those found in human Alzheimer's patients. The companies will use the mouse model to study beta-amyloid formation and to test new therapies. MMD's previous experience with Alzheimer's includes early research on a drug to enhance cognition and treat depression associated with the disease. The agreement also gives Scios "the first right to review certain cardiovascular or tissue repair products which Marion Merrell Dow decides to out-license from its product portfolio." Marion Merrell Dow is one of several firms to enter into a collaboration with Scios; other partners include Pfizer, Bayer AG, Genentech, Wyeth-Ayerst, DuPont, E. Merck and Kaken Pharmaceuticals. Scios and Pfizer are developing the gastrointestinal hormone insulinotropin for treatment of Type II diabetes, for which two patents have been issued, Scios announced July 9. The patents are owned by Massachusetts General Hospital and licensed exclusively to Scios. Scios also announced July 7 that the waiting period for Federal Trade Commission review of its proposed merger with Baltimore-based Nova Pharmaceutical has expired without any FTC request for additional information. The new company, Scios-Nova Inc., will retain Scios' California headquarters and its President and CEO Richard Casey ("The Pink Sheet" May 18, T&G-9).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel